Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_1
2
67%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(2)
Other(1)

Detailed Status

Withdrawn2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 12 (100.0%)

Trials by Status

unknown133%
withdrawn267%

Recent Activity

0 active trials
Showing 3 of 3
withdrawnphase_1

Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma

NCT04116359
withdrawnphase_1

Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas

NCT03925428
unknown

Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma

NCT03702036

Clinical Trials (3)

Showing 3 of 3 trials
NCT04116359Phase 1

Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma

Withdrawn
NCT03925428Phase 1

Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas

Withdrawn
NCT03702036

Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3